Indivior PLC Ordinary Shares (INDV)vsViatris Inc (VTRS)
INDV
Indivior PLC Ordinary Shares
$30.26
+5.11%
HEALTHCARE · Cap: $3.66B
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 1054% more annual revenue ($14.30B vs $1.24B). INDV leads profitability with a 17.0% profit margin vs -24.6%. INDV earns a higher WallStSmart Score of 62/100 (C+).
INDV
Buy62
out of 100
Grade: C+
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+55.6%
Fair Value
$76.75
Current Price
$30.26
$46.49 discount
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 37.1%
Attractively priced relative to earnings
19.7% revenue growth
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
3.8% earnings growth
Negative free cash flow — burning cash
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : INDV
The strongest argument for INDV centers on Operating Margin, P/E Ratio, Revenue Growth. Profitability is solid with margins at 17.0% and operating margin at 37.1%. Revenue growth of 19.7% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : INDV
The primary concerns for INDV are EPS Growth, Free Cash Flow.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
INDV profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
INDV carries more volatility with a beta of 1.19 — expect wider price swings.
INDV is growing revenue faster at 19.7% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
INDV scores higher overall (62/100 vs 50/100), backed by strong 17.0% margins and 19.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Indivior PLC Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?